Study identifier:D933YC00001
ClinicalTrials.gov identifier:NCT03706690
EudraCT identifier:2018-002294-22
CTIS identifier:N/A
A Phase III, Randomised,Double-Blind,Placebo-Controlled,Study of Durvalumab as Consolidation Therapy in Patients with Locally Advanced,Unresectable NSCLC, Who Have Not Progressed following Definitive, Platinum-Based Chemoradiation Therapy
Carcinoma, Non-Small-Cell Lung
Phase 3
No
Durvalumab
All
407
Interventional
18 Years - 130 Years
Allocation: Randomized
Endpoint Classification: -
Intervention Model: Parallel Assignment
Masking: -
Primary Purpose: Treatment
Verified 01 Aug 2024 by AstraZeneca
AstraZeneca
-
No locations available
Arms | Assigned Interventions |
---|---|
Experimental: Durvalumab Therapy Durvalumab (PD-L1 monoclonal antibody)1500 mg every 4 weeks [q4w] intravenously [iv] until clinical progression/deterioration or confirmed radiological progression) | Drug: Durvalumab Durvalumab 1500 mg every 4 weeks [q4w] intravenously [iv] until clinical progression/ deterioration or confirmed radiological progression. Other Name: MEDI4736 |
Placebo Comparator: Placebo Therapy Placebo (matching placebo for infusion every 4 weeks iv until clinical progression/deterioration or confirmed radiological progression) | Other: Placebo Matching placebo for infusion every 4 weeks iv until clinical progression/deterioration or confirmed radiological progression Other Name: Placebo |